Search

Zai Lab Ltd ADR

Uždarymo kaina

SektoriusSveikatos priežiūra

18.61 -0.05

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

18.46

Max

19.26

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-607K

-51M

Pardavimai

-28M

100M

Pelnas, tenkantis vienai akcijai

-0.46

Pelno marža

-51.215

Darbuotojai

1,784

EBITDA

4.1M

-44M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+73.82% upside

Dividendai

By Acuity

Kitas uždarbis

2026-08-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-67M

2.3B

Ankstesnė atidarymo kaina

18.66

Ankstesnė uždarymo kaina

18.61

Naujienos nuotaikos

By Acuity

100%

0%

324 / 340 reitingas Healthcare

Zai Lab Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-07-27 23:56; UTC

Correlated Moves
News

Diamondback Energy gained during after-market hours, buoyed by strong revenue growth and a favorable market position, with shares peaking above Monday's close.

2026-07-27 23:51; UTC

News
Event

UDR Inc reported second-quarter net income of $69.035 million. Shares declined in after-market trading amid concerns over flat revenue and rising costs.

2026-07-27 23:51; UTC

News

L3Harris Technologies has secured Pentagon agreements to boost missile defense production, but shares are trading lower in after-market hours.

2026-07-27 23:51; UTC

News
Social Media

Tesla Inc shares declined in after-market trading, continuing a trend of lower closes over the past four sessions amid analyst caution following its Q2 performance.

2026-07-27 23:51; UTC

News

Rivian shares rise in after-market trading as analysts upgrade outlook and boost price target ahead of earnings report on July 30.

2026-07-27 23:51; UTC

News

Cincinnati Financial Corp shares fell in after-market hours following second-quarter results that missed expectations for EPS and revenue. Earlier in the session, shares briefly rose.

2026-07-27 23:51; UTC

News
Social Media

Cadence Design Systems shares are higher in after-market trading following strong Q2 results and an increase in full-year revenue guidance to $6.26 billion to $6.34 billion.

2026-07-27 23:51; UTC

News
Social Media

Microstrategy shares declined in after-market hours following Peter Schiff's criticism of the company's Bitcoin yield, which fell significantly in recent months.

2026-07-27 23:51; UTC

News

Accenture PLC shares are lower in after-market hours despite a $2 billion share repurchase program and a quarterly dividend announcement.

2026-07-27 23:51; UTC

News

NIO shares rose in after-market trading, building on regular-session gains. Options activity showed bullish sentiment, with calls outpacing puts significantly.

2026-07-27 23:51; UTC

News
Social Media
Correlated Moves

Micron Technology Inc shares declined in after-market trading following a report raising concerns about the company's growth potential and future demand for memory chips.

2026-07-27 23:51; UTC

News
Social Media

Amkor Technology's shares declined in after-market trading following weaker-than-expected third-quarter revenue guidance despite strong second-quarter results and earnings.

2026-07-27 23:42; UTC

News
Correlated Moves

Bitcoin is trading lower as easing geopolitical tensions reduce demand for safe-haven assets. Ethereum also declines, reflecting its correlation with Bitcoin's market movements.

2026-07-27 23:42; UTC

Correlated Moves
News

Bitcoin is trading lower as easing geopolitical tensions reduce demand for safe-haven assets. Ethereum also declines amid similar market dynamics.

2026-07-27 23:41; UTC

News
Correlated Moves

NBT Bancorp shares are higher in after-market trading following second-quarter results, which included net income of $53 million and a dividend increase to $0.40 per share.

2026-07-27 23:41; UTC

News
Social Media

Brown & Brown Inc reported second-quarter revenues of $1.68 billion, missing expectations. Shares are trading lower in after-market hours following the mixed results.

2026-07-27 23:41; UTC

News

OPKO Health reported second-quarter revenues of $163.5 million, surpassing expectations. The company also raised its full-year sales guidance, boosting shares in after-market trading.

2026-07-27 23:41; UTC

News

International Paper shares are higher in after-market trading as CEO Andy Silvernail prepares to present at the Jefferies 2026 Industrials Conference on September 10.

2026-07-27 23:41; UTC

News

Oil prices are higher in after-market hours, supported by reduced supply disruption concerns from the Middle East and gains in European markets.

2026-07-27 23:31; UTC

News

Northwest Bancshares reported second-quarter adjusted EPS of $0.37 and revenue of $181.2 million, exceeding expectations. Shares are trading higher in after-market hours.

2026-07-27 23:31; UTC

News
Social Media

Johnson & Johnson shares are higher in after-market trading following a proposed $5.5 billion settlement for ovarian talc litigation involving about 76,000 claims.

2026-07-27 23:31; UTC

News
Social Media

ServiceNow shares rose during after-market hours as software stocks recovered. CEO Bill McDermott reported no slowdown in demand amid mixed social media sentiment on AI impacts.

2026-07-27 23:26; UTC

News

Nucor Corporation reported second-quarter earnings of $1.16 billion, exceeding estimates. Shares are trading higher in after-market hours following the strong results.

2026-07-27 23:16; UTC

News
Social Media

Intel Corp shares are lower in after-market hours following a $2.1 billion loss, despite a 25% revenue increase to $16.1 billion in Q2.

2026-07-27 23:16; UTC

News

Dell Technologies Inc. shares are lower in after-market hours, continuing a trend from the previous three sessions amid a focus on AI-optimized infrastructure solutions.

2026-07-27 23:16; UTC

News

Zoetis shares are lower in after-market hours following a class action lawsuit alleging securities fraud and reduced profit guidance to between $6.85 and $7.00 per share.

2026-07-27 23:11; UTC

News

Albertsons Companies Inc shares are lower in after-market hours amid an investigation into potential securities law violations and a Q1 EPS miss of $0.42.

2026-07-27 23:02; UTC

News
Social Media

Welltower reported strong Q2 results, raising full-year FFO guidance and increasing its dividend. Shares are trading higher in after-market hours.

2026-07-27 23:02; UTC

News
Social Media

Sanmina Corp shares are lower in after-market trading despite strong Q3 results, as Q4 guidance fell short of consensus estimates.

2026-07-27 23:02; UTC

News

GoPro Inc. will release its Q2 financial results on August 10, 2026, contributing to a higher after-market price as investors anticipate insights.

Akcijų palyginimas

Kainos pokytis

Zai Lab Ltd ADR Prognozė

Kainos tikslas

By TipRanks

73.82% į viršų

12 mėnesių prognozė

Vidutinis 32.4 USD  73.82%

Aukščiausias 44 USD

Žemiausias 21.6 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Zai Lab Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

3

Pirkti

1

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

324 / 340 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat